Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection
Clinical Gastroenterology and Hepatology, Volume 3, No. 6, Year 2005
Notification
URL copied to clipboard!
Description
Background & Aims: Pegylated interferon alfa-2b (PEG-IFN-alfa 2b) has been shown to provide superior efficacy to IFN-alfa 2b in patients with chronic hepatitis C (predominantly genotype 1) infection as measured by viral clearance. This study was conducted to determine the optimal dosing regimen of PEG-IFN-alfa2b required to obtain a maximum decrease of hepatitis C viral RNA. Methods: This was a 24-week, open-label, multicenter, parallel-group, randomized, active-controlled trial in the United Kingdom, France, and Israel. Individuals (n = 61) with chronic hepatitis C infection, genotype 1, received IFN-alfa2b 3 mIU 3 times weekly for 24 weeks, or PEG-IFN-alfa2b 1.5 or 3.0 μg/kg/wk, as total weekly full or split doses, for 12 weeks. At week 12, serum RNA titer was measured, and all PEG-IFN-alfa2b patients continued with 1.5 μg/kg/wk for a further 12 weeks. Results: Mean serum hepatitis C RNA levels decreased in all groups at weeks 12 and 24. PEG-IFN-alfa2b 1.5 μg/kg/wk was superior to IFN-alfa2b in decreasing mean serum hepatitis C RNA (P <. 05 at week 12). The efficacy of split-dose PEG-IFN-alfa2b 1.5 or 3.0 μg/kg/wk regimens was not significantly different from full-dose PEG-IFN-alfa2b 1.5 μg/kg/wk. However, there was a significant decrease in neutrophil count in groups receiving PEG-IFN-alfa2b 3.0 μg/kg/wk or lower, multiple-dose per week regimens. Conclusions: PEG-IFN-alfa2b 1.5 μg/kg once weekly is the optimal dosing frequency for patients with chronic hepatitis C with predominantly genotype 1 infection. More frequent dosing or increasing the dose to 3.0 μg/kg/wk did not result in improved antiviral effects, but did decrease neutrophil counts. © 2005 by the American Gastroenterological Association.
Authors & Co-Authors
Lurie, Yoav
Israel, Tel Aviv-yafo
Tel Aviv Sourasky Medical Center
Webster, George J.M.
United Kingdom, London
Ucl Medical School
Dusheiko, Geoffrey M.
United Kingdom, London
Ucl Medical School
Statistics
Citations: 6
Authors: 3
Affiliations: 3
Identifiers
Doi:
10.1016/S1542-3565(04)00723-2
ISSN:
15423565
Research Areas
Genetics And Genomics
Infectious Diseases